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In ReplyWe recently reported that high bodymass index (BMI)
and lowaerobic fitness in a large cohort of 18-year-old Swedish
menwereassociatedwithincreasedriskofhypertensioninadult-
hood.Hypertensionwasascertainedusingall inpatientdiagnoses
nationwide throughout the study period (1969-2012) and out-
patient diagnoses from all specialty clinics between 2001 and
2012. We indicated that hypertension was therefore under-
reportedbecausewelackedoutpatientdatabefore2001or from
primarycareclinics.DrBrunströmraisesthequestionofwhether
our findingsmaybe attributable to the knownassociations be-
tweenhighBMIor lowaerobicfitnessandcoronaryheartdisease
orstrokethatarelikelytoreceiveinpatientorspecialtyclinictreat-
ment and are also associatedwith hypertension.
Weperformedsensitivity analyses toexplore thispossibil-
ityfurther.Wefoundthatonlyasmallminorityofmenwhowere
diagnosedwithhypertension (n = 93035) hada concurrent or
earlier diagnosis of ischemicheart disease (n = 13 523 [14.5%])
or stroke (n = 5368 [5.8%]). When we repeated our analyses
after excluding these individuals, the findings were largely
unchanged. High BMI and low aerobic capacity remained
associatedwithan increasedriskofhypertension, independent
of familyhistory and socioeconomic factors (BMI, overweight
orobesevsnormal: incidencerateratio [IRR],2.62;95%CI,2.57-
2.67;P < .001; aerobic capacity, lowest vs highest tertile: IRR,
1.43; 95% CI 1.39-1.46; P < .001). Alternatively, adjusting for
ischemicheartdiseaseandstrokeas time-dependentvariables
yieldedverysimilarresults.Otherfindingsalsowereunchanged:
highBMIand lowaerobic capacityhadanegative additive and
multiplicative interaction (P < .001), and lowaerobic capacity
remainedasignificant risk factoramongthosewithnormalBMI
(lowest vshighest tertile: IRR, 1.52; 95%CI 1.48-1.57;P < .001).
These supplemental findings suggest that the associationswe
reportedwerenot spuriously causedby ascertainment bias or
confounding by ischemic heart disease or stroke.
Our findings are also consistentwith other epidemiologic
andbiologicevidence linkingobesityor lowaerobic fitnesswith
ahigher risk of developinghypertension.Anumber of smaller
epidemiologic studies have reported similar associations be-
tween high BMI1,2 or low aerobic fitness3,4 and risk of hyper-
tension. These studies ascertained hypertension in various
ways, including direct blood pressure measurements,3 chart
review,4orself-report.1,2Experimental studieshaveshownthat
theunderlyingmechanisms aremultifactorial and involve in-
creased catecholamine secretion and activity, insulin resis-
tance,andotherneuroendocrineandmetaboliceffectsonsym-
patheticactivationandendothelialandvasculardysfunction.5,6
Because associations between obesity or low aerobic fitness
and hypertension are well-established, the main purpose of
our study was to explore their interactive effects.
We found thathighBMIand lowaerobic fitness in late ado-
lescencewere associatedwithhigher long-term risk of hyper-
tensionandhadanegative interaction.These findingsare con-
gruentwitha largebodyofepidemiologicandbiologicevidence
anddidnot appear to be causedby ascertainment bias or con-
founding. Thepreponderance of evidence suggests thatmea-
sures to prevent hypertension should begin early in life and
includenotonlyweight control, butaerobic fitnesseven inper-
sons of normal weight.
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QuestioningNicotine Replacement Therapy
Without Behavioral Support
To the Editor We enjoyed reading the article by Cunningham
et al1 in a recent issue of JAMA Internal Medicine that dem-
onstrated an effect of mailing smokers nicotine replacement
therapy (NRT) without behavioral support on 6-month
abstinence from smoking.1 One important reason for per-
forming this trial, as noted by the authors, was that “popu-
lation survey data comparing those who used NRT (ob-
tained over-the-counter) during a quit attempt and those
who did not use NRT has found no association between use
of NRT and an increase in success rates.”1(p185) This state-
ment refers to a cross-sectional study and a prospective
cohort study we recently performed in England.2,3 However,
Cunningham et al did not register the crucial distinction we
made in these 2 studies between NRT bought over-the-
counter and used without behavioral support and NRT
received on prescription (NRT Rx) and used with brief
advice from the prescribing physician. Compared with
unaided quitting, NRT bought over-the-counter was indeed
not effective whereas NRT Rx was (cross-sectional study,2
odds ratio [OR], 1.62; 95% CI, 1.33-1.94; and prospective
cohort study,3 OR, 1.55; 95% CI, 1.11-2.16).
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In the trialbyCunninghametal, smokers interested inquit-
tingwithin1weekreceivednicotinepatchesalongwith“acover
letter instructing themon the use of the patches and advising
them to talk to their physician or pharmacist if they had any
further questions.”1(p186)While this represented excellent ad-
vice andproduced a very solid effect, itwas somewhat differ-
ent fromthewaysmokersnormallyuseNRTwhenboughtover-
the-counter as assessed inour studies.Anotherpossible factor
is that smokers were proactively approached and had to give
verbal consent toa longitudinal study inwhich theyhadtosub-
mit saliva samples to verify their abstinence from smoking at
3 time points. They also received a financial incentive of $20
at each time point to return the saliva sample.
The current studymakes an important contribution to the
literature in demonstrating an effect ofNRT in themost natu-
ralistic trial todate.Wealsoacknowledge thatconducting these
types of pragmatic trials is an incredibly difficult (and admi-
rable) topic for research. However, we suggest that the find-
ings of the current study do not necessarily contradict the
previous failure to find an effect of NRT just bought from a
shop, though they do point to a wide-reach, low-intensity
way of providing NRT that is effective.
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In ReplyThearticle byCunninghamet al1 and the letter byKotz
et al report on similar topics but come fromdifferent research
traditions. As such, they serve as a good illustration of the
strengthsand limitationsof randomizedclinical trial (RCT)and
epidemiological survey research methods and can highlight
the synergistic benefits of employing multiple different
research methods exploring the same topic.
The strength of the RCT method used in the trial by
Cunningham et al1 is that it allows for statements of causa-
tion, finding that participants who were sent the nicotine
patches (along with a letter) were more likely to report quit-
ting smoking compared with participants not sent the nico-
tine patches. The letter by Kotz et al points out several valid
limitations. Primarily, the steps taken to recruit the partici-
pants resulted in a sample that was not representative, mak-
ing it important to be cautious as to whether the same out-
comes would occur in the general population of smokers.
The letter byKotz et al references a cross-sectional study2
and a prospective cohort study3 that indicate, while pre-
scribednicotine replacement therapy (NRT) is associatedwith
increased tobacco cessation rates, NRT purchased over-the-
counter (OTC) is not. The strengthof these surveys is that they
provide a fairly accurate snapshot ofwhat is actually going on
inthegeneralpopulationofsmokers.The limitationof thestud-
ies is that the results cannot be used to make causal state-
ments about whether it is the NRT or another systematic dif-
ferencebetween thosewhoget theirNRTthroughprescription
vs OTC (and those who try to quit without using NRT at all)
that leads to the observed findings.
The real strength of a cumulative research endeavor is
observed when these studies are examined together. The
articles referenced by Kotz et al2,3 note the lack of relation
between NRT purchased OTC and increased rates of tobacco
cessation. One possible explanation for this lack of observed
effect is that NRT provided by prescription may be accompa-
nied by behavioral support but that NRT purchased OTC is
not. The article by Cunningham et al1 partially addresses this
possible explanation, indicating that NRT without behav-
ioral support can increase tobacco cessation rates. This leads
to an accumulation of evidence and helps narrow the range
of possible explanations regarding why people purchasing
an OTC NRT may be no more likely to have increased
tobacco cessation rates than people who attempt to quit
without using NRT at all. This narrowing of possibilities then
brings into focus research questions regarding the potential
effect of OTC NRT as a means of promoting tobacco cessa-
tion in the general population. That is, if it is not the behav-
ioral support that differentiates the observed differential
effect between NRT when provided as a prescription vs
when purchased OTC, then what else is going on and what
can be done to promote the impact of OTC NRT? These ques-
tions would benefit from the participation of other research
traditions, such as those specializing in qualitative methods,
to shed light on this intriguing issue and to generate hypoth-
eses that can then be tested using RCT and epidemiological
surveys.
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LESS ISMORE
Estimating Vitamin D Status and the Choice
of Supplementation Dose
To the Editor In a recent issue of JAMA Internal Medicine,
Bischoff-Ferrari and colleagues1 reported the results of an
interesting randomized clinical trial testing the efficiency of
physiological (equivalence, 800 IU/d) and supraphysiologi-
cal doses (equivalence, 2000 IU/d or 800 IU/d plus calcife-
diol 300 μg/mo) of vitamin D supplements in lowering the
risk of functional decline. The authors found that older par-
ticipants in the higher-dose vitamin D groups experienced
the greater incidence of falls,1 a result already described
with mega doses of vitamin D supplementation2 but in
contradiction with the well-recognized antifall effect of
physiological doses.3
Before claiming that high-dose vitamin D supplementa-
tion makes seniors fall, we wish to draw attention to the
secondary analyses stratified by initial vitamin D status.1
The 12-month number of falls was greater after high-dose
vs low-dose vitamin D supplementation only in the group
that had no hypov i t aminos i s D at base l ine ( i e ,
25-hydroxyvitamin D [25(OH)D] ≥ 20 ng/mL [to convert
25[OH]D level to nanomoles per liter, multiply by 2.496]),
but not in the group with initial hypovitaminosis D less
than 20ng/mL (P = .03 and P = .33, respectively). It thus
appears that, among people without hypovitaminosis D,
high-dose vitamin D supplementation, aimed at increasing
25(OH)D concentration to supraphysiological levels, is
probably not useful—and might be toxic—compared
with lower doses aiming at preventing hypovitaminosis D
and maintaining 25(OH)D concentration to physiological
levels.
These data confirm the current hypothesis of a possible
U-shaped or J-shaped effect of vitamin D, with both low and
high 25(OH)D concentrations being associated with adverse
health events.4 For this reason, we call for the need to deter-
mine older individuals’ vitamin D status before any vitamin
D supplementation. However, we recognize that such sys-
tematic screening for hypovitaminosis D is currently com-
promised in this population due to the cost of 25(OH)D
assay, which is higher than the annual supplementation. To
avoid the current trend toward universal supplementation
on sight, and to help determining which individuals should
receive lower-dose or higher-dose vitamin D supplements,
it is urgently needed to develop new cost-effective routine
screening strategies to provide an appropriate medical
decision. For instance, we recently developed a clinical tool
able to identify older adults with hypovitaminosis D who
may be administered high-dose supplements without blood
test.5 Further investigations will be necessary to examine
the feasibility, cost-effectiveness, and usefulness of such
tools in daily practice and to estimate if they allow supple-
menting older adults in a personalized way, thus avoiding
vitamin D toxic effects described by Bischoff-Ferrari and
colleagues.
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In ReplyWeagree thathigh-dosemonthlyvitaminD isnotnec-
essarily harmful among seniors with vitamin D deficiency.
However, everyone treated with 24 000 IU vitamin D per
month (equivalent to 800 IU/day) achieved the replete range
of above20ng/mL25(OH)D (to convert 25[OH]D level tonano-
moles per liter, multiply by 2.496), with none reaching a
25(OH)D level above45ng/mL.1Thegroup treatedwith24000
IU per month included 59.7% of participants with deficient
25(OH)Dstarting levels less than20ng/mLand40.3%with re-
plete 25(OH)D starting levels greater than 20 ng/mL (range,
20.1-43.5ng/mL). Thus, at starting levels throughout thewide
rangeof4.9 to43.5ng/mL, 24000 IUvitaminDpermonthap-
pears tobeeffective in safelybringing25(OH)D levels intowhat
currently appears tobe thedesirable range for fall prevention.1
Thisdoesnotmean thatmeasuring25(OH)Dstatus isnever in-
dicated but suggests that wide spread assessments by serum
analysis or algorithmmay not be necessary.
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